Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease

Gut

Volumn 58, Issue 9, 2009, Pages 1218-1225

  Sokol, H ^a   Polin, V ^b   Lavergne Slove, A ^b   Panis, Y ^c   Treton, X ^c   Dray, X ^b,d   Bouhnik, Y ^c   Valleur, P ^b   Marteau, P ^b,d  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c BEAUJON HOSPITAL   (France)

^d Bioinformatique et Chimie Moléculaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CD3 ANTIBODY; EOSIN; HEMATIN; METHOTREXATE; PURINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CECUM CARCINOMA; COLON RESECTION; CONTROL GROUP; CONTROLLED STUDY; CROHN DISEASE; DISEASE FREE INTERVAL; EOSINOPHIL; FEMALE; FOLLOW UP; FRANCE; HUMAN; HUMAN TISSUE; ILEUM RESECTION; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MAST CELL; MEDICAL RECORD; MULTIVARIATE ANALYSIS; MYENTERIC PLEXITIS; POSTOPERATIVE COMPLICATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SMOKING; STAINING; SUBMUCOSAL PLEXITIS;

ADULT; AUTONOMIC NERVOUS SYSTEM DISEASES; CASE-CONTROL STUDIES; COLON; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; ILEUM; IMMUNOHISTOCHEMISTRY; MALE; MAST CELLS; MYENTERIC PLEXUS; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK; T-LYMPHOCYTES;

EID: 68849110738     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.177782     Document Type: Article

References (51)

1. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000;231:38-45.
2. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-41.
3. Fichera A, Lovadina S, Rubin M, et al. Patterns and operative treatment of recurrent Crohn's disease: a prospective longitudinal study. Surgery 2006;140:649-54.
4. Avidan B, Sakhnini E, Lahat A, et al. Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion 2005;72:248-53.
5. Breuer-Katschinski BD, Hollander N, Goebell H. Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol 1996;8:225-8.
6. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55(Suppl 1):i36-58.
7. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63.
8. Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990;98:1123-8.
9. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004;127:730-40.
10. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
11. Cottone M, Camma C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology 2000;119:597.
12. D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008;135:1123-9.
13. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127:723-9.
14. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
15. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856-61.
16. Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005;242:693-700.
17. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55(Suppl 1):i16-35.
18. Aeberhard P, Berchtold W, Riedtmann HJ, et al. Surgical recurrence of perforating and nonperforating Crohn's disease. A study of 101 surgically treated patients. Dis Colon Rectum 1996;39:80-7.
19. Chambers TJ, Morson BC. The granuloma in Crohn's disease. Gut 1979;20:269-74.
20. Glass RE, Baker WN. Role of the granuloma in recurrent Crohn's disease. Gut 1976;17:75-7.
21. Kotanagi H, Kramer K, Fazio VW, et al. Do microscopic abnormalities at resection margins correlate with increased anastomotic recurrence in Crohn's disease? Retrospective analysis of 100 cases. Dis Colon Rectum 1991;34:909-16.
22. Antonius JI, Gump FE, Lattes R, et al. A study of certain microscopic features in regional enteritis, and their possible prognostic significance. Gastroenterology 1960;38:889-905.
23. Geboes K, Rutgeerts P, Ectors N, et al. Major histocompatibility class II expression on the small intestinal nervous system in Crohn's disease. Gastroenterology 1992;103:439-47.
24. Stead RH, Dixon MF, Bramwell NH, et al. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology 1989;97:575-85.
25. Grundy D, Schemann M. Enteric nervous system. Curr Opin Gastroenterol 2007;23:121-6.
26. Ferrante M, de Hertogh G, Hlavaty T, et al. The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence. Gastroenterology 2006;130:1595-606.
27. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53.
28. Kay R. Goodness of fit methods for the proportional hazards regression model: a review. Rev Epidemiol Sante Publique 1984;32:185-98.
29. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut 2006;55:1512-20.
30. Greenwood B, Mantle M. Mucin and protein release in the rabbit jejunum: effects of bethanechol and vagal nerve stimulation. Gastroenterology 1992;103:496-505.
31. Neunlist M, Toumi F, Oreschkova T, et al. Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. Am J Physiol Gastrointest Liver Physiol 2003;285:G1028-36.
32. Savidge TC, Newman P, Pothoulakis C, et al. Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology 2007;132:1344-58.
33. Abad C, Gomariz RP, Waschek JA. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr Top Med Chem 2006;6:151-63.
34. Weinstock JV, Blum A, Metwali A, et al. Substance P regulates Th1-type colitis in IL-10 knockout mice. J Immunol 2003;171:3762-7.
35. Ruhl A, Franzke S, Collins SM, et al. Interleukin-6 expression and regulation in rat enteric glial cells. Am J Physiol Gastrointest Liver Physiol 2001;280:G1163-71.
36. Knutson L, Ahrenstedt O, Odlind B, et al. The jejunal secretion of histamine is increased in active Crohn's disease. Gastroenterology 1990;98:849-54.
37. Breunig E, Michel K, Zeller F, et al. Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J Physiol 2007;583:731-42.
38. Corvera CU, Dery O, McConalogue K, et al. Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and -2. J Physiol 1999;517:741- 56.
39. Raithel M, Winterkamp S, Pacurar A, et al. Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 2001;36:174-9.
40. Cenac N, Chin AC, Garcia-Villar R, et al. PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways. J Physiol 2004;558:913-25.
41. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000;6:151-8.
42. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994;106:643-8.
43. Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1998;114:1143-50.
44. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996;110:424-31.
45. Klein O, Colombel JF, Lescut D, et al. Remaining small bowel endoscopic lesions at surgery have no influence on early anastomotic recurrences in Crohn's disease. Am J Gastroenterol 1995;90:1949- 52.
46. Wolfson DM, Sachar DB, Cohen A, et al. Granulomas do not affect postoperative recurrence rates in Crohn's disease. Gastroenterology 1982;83:405-9.
47. Pennington L, Hamilton SR, Bayless TM, et al. Surgical management of Crohn's disease. Influence of disease at margin of resection. Ann Surg 1980;192:311-8.
48. Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized controlled trial. Ann Surg 1996;224:563-71; discussion 71-3.
49. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6.
50. Siproudhis L, Mortaji A, Mary JY, et al. Anal lesions: any significant prognosis in Crohn's disease? Eur J Gastroenterol Hepatol 1997;9:239-43.
51. Cottone M, Orlando A, Viscido A, et al. Review article: prevention of postsurgical relapse and recurrence in Crohn's disease. Aliment Pharmacol Ther 2003;17(Suppl 2):38-42.